HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate's Ups, Downs In Bicoastal Fight Against Talc Mesothelioma Suits

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson isn't the only personal-care giant embroiled in litigation over talcum powders' alleged cancer links. Colgate-Palmolive is battling suits in Pennsylvania and California alleging that plaintiffs' mesothelioma was caused by asbestos-tainted talc in Cashmere Bouquet products sold by the firm until the mid-1990s.

You may also be interested in...



Cosmetic Talc Under Scrutiny As Liability Buzzards Circle

Plaintiff’s attorneys are tracking reports of asbestos-contaminated cosmetics at specialty retail stores, signaling a possible new wave of talc-related litigation to come. The issue also has the attention of NGOs, legislators and FDA.

‘Asbestos-Free’ A Relative Term? SAI Testing Expert On Cosmetic Talc Challenges

Transmission electron microscopy is likely the safest bet, among other imaging technologies, for companies looking to verify their cosmetic talc as asbestos-free. However, there’s no regulatory-mandated method for cosmetics purposes, which may explain conflicting results being reported by different labs.  

J&J’s Talc Winning Streak Continues With Calif. Mesothelioma Verdict

A California jury sided with J&J Nov. 16 in the first trial over whether alleged asbestos in the firm's talcum powders caused plaintiff's mesothelioma. The verdict could help check what threatens to be a new field of litigation against J&J for alleged talc dangers, and the firm also is gaining momentum in its defense against ovarian cancer claims.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel